Does Gilenya Cause a Decrease in Heart Rate?
Yes, Gilenya (fingolimod) causes a transient decrease in heart rate, primarily through its activation of sphingosine-1-phosphate (S1P) receptors in cardiac tissue. This bradycardycardia effect peaks within 6 hours of the first dose and typically resolves within 24 hours as heart rate returns to baseline.[1][2]
How Does This Heart Rate Effect Happen?
Gilenya traps lymphocytes in lymph nodes to reduce multiple sclerosis relapses, but it also binds S1P receptors on atrial myocytes. This slows sinoatrial node firing and atrioventricular conduction, leading to a dose-dependent drop—often 10-20 beats per minute, with maximum reductions around 13 bpm in trials.[1][3] Subsequent doses rarely cause recurrence due to receptor downregulation.
What Do Clinical Trials Show?
In phase 3 trials (FREEDOMS and TRANSFORMS), first-dose bradycardia occurred in 0.5-5% of patients, with AV block in under 1%. Heart rate fell by an average 8-12 bpm, more pronounced in those with lower baseline rates. No deaths linked to this effect, but monitoring is standard.[2][4]
Who Gets Monitored and for How Long?
FDA requires 6-hour post-first-dose observation in a medical facility with ECG, blood pressure, and heart rate checks hourly. This applies to all patients starting Gilenya, including re-starts after interruption. No routine monitoring needed for later doses unless symptoms appear.[1][5] High-risk groups (prior bradycardia, beta-blockers, or heart conditions) may need extended watch or pre-treatment cardiology consult.
What Are the Common Heart-Related Side Effects?
Bradycardia (4-14% incidence), first-degree AV block (4-5%), and rare second-degree block (0.5%). Symptoms like dizziness or fatigue can occur but are usually asymptomatic. Contraindicated in recent myocardial infarction, unstable angina, stroke, or class III/IV heart failure.[1][2]
Can You Take It with Heart Medications?
Avoid starting with beta-blockers, calcium channel blockers (e.g., diltiazem, verapamil), or digoxin—titrate these first or monitor closely to prevent additive slowing. Class Ia/Ic antiarrhythmics are contraindicated.[1][3]
How Long Until Heart Rate Normalizes?
Return to baseline within 1 day for most; full adaptation by day 2-4. Long-term use shows no sustained bradycardia.[2][4]
[1]: Gilenya Prescribing Information (Novartis)
[2]: FDA Label for Fingolimod
[3]: EMA Summary of Product Characteristics
[4]: Kappos L, et al. N Engl J Med 2010;362:387-401 (FREEDOMS trial).
[5]: Cohen JA, et al. N Engl J Med 2010;362:402-15 (TRANSFORMS trial).